This is in contrast to the amount of GLP-1 in semaglutide and other weight loss medications which lasts for days
In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
Body composition changes usually take longer and depend on nutrition, exercise, sleep, lab results, dosing, and consistency
For example, carriers may require the presence of a certain BMI and/or a weight-related condition, and may not offer coverage until other treatment modalities have been excluded
SURPASS 1, SURPASS 5, and SURPASS J-combo are placebo controlled, while others have active comparators: for example GLP-1RAs (dulaglutide and semaglutide), long-acting insulin analogues (glargine and degludec), or short-acting insulin analogue (lispro)
Cognitive function modulation during aging: a focus on L-alpha-GPE